Victrex plc

FY25 revenue was GBP 292.7 million, up 1% year over year and up 3% in constant currency. Sales volume increased 12% to 4,164 tonnes. Gross profit was GBP 132.6 million, down 1%, and gross margin was 45.3%, down 90 basis points. Underlying PBT was GBP 46.4 million, down 21% and down 10% in constant currency; reported PBT was GBP 33.8 million, up 44%. Underlying EPS was 43.9p, down 15%. The final dividend was maintained at 46.14p per share. Cash conversion was 121%, CapEx was GBP 21.8 million, and net debt to EBITDA was 0.34x. For FY26, management is targeting low to mid-single-digit volume growth, ASP similar to FY25, gross margin flat to slightly ahead, continued strong cash conversion, and at least GBP 10 million of savings from the profit improvement plan, with most of that benefit landing in FY27.

Jakob Sigurdsson emphasized that FY25 was challenging, but said Victrex remains a world leader in PEEK with a large long-term market opportunity and strong structural demand drivers such as metal replacement and clinical benefits. He highlighted the new profit improvement plan and said the company will simplify parts of the portfolio and dynamically allocate resources to the projects that can shorten time to commercialization. His tone was defensive on near-term conditions but confident about the long-term positioning of the business.

Ian Melling walked through the year’s margin pressure in detail: revenue grew only 1% to GBP 292.7 million, gross profit was GBP 132.6 million, gross margin was 45.3%, and underlying PBT was GBP 46.4 million. He pointed to an GBP 8 million currency headwind, softer ASPs, annualized China plant costs, and wage inflation, while also noting GBP 6 million of benefit from higher asset utilization and GBP 4.7 million from raw materials. Cash performance remained strong, with 121% cash conversion, GBP 49.3 million of free cash flow, CapEx down 33% to GBP 21.8 million, and net debt of GBP 24.8 million. He also said interest expense should be similar in FY26 and that the effective tax rate will again exceed the top end of the midterm 15% to 19% range due to China losses and Patent Box mix.

Analysts focused on China ramp-up, pricing, Medical Spine weakness, knee and trauma programs, and whether the sales pipeline would translate into earnings. Management said China is still working through start-up issues, but customer demand is roughly in line with what was delivered in FY25 and the plant is strategically important in a fast-growing market. On pricing, management said FY26 ASP should be broadly stable because the big FY25 decline was mostly mix and currency rather than pure price, though some pressure remains in VARs. On medical, they said knee recruitment is initially slow and not directly controllable, trauma is delayed by customer and regulatory issues, and the sales pipeline is large but typically converts over 2 to 3 years at around 30% to 40% gross conversion.